New Drug Channels Institute Study Analyzes U.S. Drug Pricing And Rebates, Predicts Further Shakeout and Consolidation

Share Article

DCI releases tenth edition of its comprehensive report on the U.S. drug pricing, reimbursement, and dispensing system

The likelihood of a radical restructuring of the U.S. drug channel has never been greater.

Today Drug Channels Institute, a leading management educator for and about the pharmaceutical industry, released its exclusive, in-depth analysis of U.S. pharmacies and pharmacy benefit managers (PBMs). The new 2019 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers provides the most comprehensive, fact-based tool for understanding the entire U.S. drug pricing, reimbursement, and dispensing system.

“Vertical and horizontal mergers and acquisitions are reshaping the pharmacy and PBM industries—and enabling the big to get even bigger,” says Drug Channels Institute CEO Adam J. Fein, Ph.D., the study's author and a widely regarded expert on pharmaceutical economics and the drug distribution system. “Seven companies accounted for 70% of U.S. prescription dispensing revenues in 2018, and three PBMs processed more than 75% of equivalent prescription claims. The pharmacy industry faces the prospect of a shakeout that will sharply reduce the number of U.S. retail pharmacy locations.”

These findings are among the many insights and trends in this highly regarded report, now in its tenth edition. With 180 proprietary charts, exhibits, and data tables, it offers the most current economic information about specialty drugs, market structure, reimbursement models, pharmacy and PBM profits, manufacturer rebates, patients’ out-of-pocket expenses, forces of change, and more.

“The gross-to-net bubble has created large marketplace distortions for payers, PBMs, patients, and manufacturers,” Fein adds. “The likelihood of a radical restructuring of the U.S. drug channel has never been greater.”

The report analyzes the crucial healthcare trends that will affect PBMs and pharmacies, including such topics as benefit designs, drug pricing, rebate system reform, narrow networks, the 340B Drug Pricing Program, and much more. This year’s edition also includes new material about nontraditional players—including hospitals, Amazon, and venture-backed start-ups—that are expanding their role in the pharmacy industry.

To purchase and immediately download the new report, visit To read a free report overview, visit

About Drug Channels Institute

Drug Channels Institute, a division of Pembroke Consulting, Inc., is a leading provider of specialized management education and computer-based training for and about the pharmaceutical industry. To access Dr. Fein’s popular Drug Channels blog, visit

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Tamra Feldman
Follow >